Gujarat Themis Biosyn Ltd

BSE: 506879 NSE: GUJTHEM
Gujarat Themis Biosyn Ltd - pharma in Valsad, Gujarat, India. FY 2026 financials & compliance.
CIN L24230GJ1981PLC004878 Incorporated 11 December 1981 ROC Ahmedabad HQ Valsad, Gujarat, India
Active Listed - NSE: GUJTHEM · BSE: 506879 Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹5,051 Cr
GUJTHEM · NSE
Share Price
₹380.20
-2.04% today
Revenue
₹166 Cr
FY 2025-26 · +10.0% YoY
EBITDA
₹76.41 Cr
Margin 46.1%
Net Profit
₹46.67 Cr
FY 2025-26 · -4.3% YoY
P/E (TTM)
108.1x
P/B 6.7x
ROE
17.4%
ROCE 18.1%
Debt / Equity
0.36
Interest cover 6.0x

About Gujarat Themis Biosyn Ltd

Data last updated:

Gujarat Themis Biosyn Ltd is a public limited company based in Valsad, Gujarat, India, a subsidiary of Pharmaceutical Business Group(Indipharmaceutical Business Group(India) Limiteda) Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 11 December 1981 and has been in existence for over 45 years.

Its director Dinesh Shantilal Patel and family are #912 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1981PLC004878. Its GSTIN is 24AABCG0802C1ZJ (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 506879 and NSE: GUJTHEM.

The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹10.9 Cr. It is led by directors including Sachin Dinesh Patel (Managing Director) and Dinesh Shantilal Patel.

Its last annual general meeting (AGM) was held on 12 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 69/C GIDC Industrial Estate Vapi, Valsad, Gujarat, India – 396195.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹165.82 Cr, a growth of 10% compared to the previous year. For the same year it recorded a net profit of ₹46.67 Cr (net margin 28.1%) and EBITDA of ₹76.41 Cr (EBITDA margin 46.1%). The net worth stands at ₹287.77 Cr (up 15.9% YoY). Total assets are valued at ₹450.79 Cr (up 61.2% YoY).

The company has about 354 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Gujarat Themis Biosyn. As per MCA filings, the company has open charges of ₹197.18 Cr and satisfied charges of ₹48.84 Cr on record. Court records list 125 cases involving the company, including 29 filed by the company and 96 filed against it; 12 cases are pending. The company has 8 deals on record (8 market trades); the latest was in September 2026. The company has 13 MSME Form 1 returns on record between 2019 and 2023, listing 668 overdue payments to 14 micro and small suppliers.

Gujarat Themis Biosyn Ltd is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-25-0006960). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gtbl.in.

Company details

CIN L24230GJ1981PLC004878
Registration Number 004878
Incorporation Date 11 December 1981
ROC Ahmedabad
Listing Status Listed - Listed on NSE (GUJTHEM); Listed on BSE (506879)
Company Status Active
Date of Last AGM 12 September 2025
Date of Balance Sheet 31 March 2026
Parent Company Pharmaceutical Business Group(Indipharmaceutical Business Group(India) Limiteda) Limited
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-25-0006960

CIN history

Gujarat Themis Biosyn has one previous CIN (Corporate Identification Number): U24230GJ1981PLC004878. The current CIN is L24230GJ1981PLC004878, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230GJ1981PLC004878Current
U24230GJ1981PLC004878Previous
Key People
Sachin Dinesh Patel Managing Director Dinesh Shantilal Patel Director Kirandeep Kaur Madan Director

Recognitions & Rankings of Gujarat Themis Biosyn

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-GJ-25-0006960

Contact details

Gujarat Themis Biosyn Ltd's registered office is in Valsad, Gujarat. Its website is gtbl.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    gtbl.in
  • Social Media
  • Registered Address
    69/C GIDC Industrial Estate Vapi, Valsad, Gujarat, India – 396195
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Gujarat Themis Biosyn Ltd, buy the company report.

Comprehensive company report
Gujarat Themis Biosyn Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Gujarat Themis Biosyn operates one associated brand: Gujarat Themis Biosyn. Each brand links to its own profile.

BrandDescriptionWebsite
Gujarat Themis Biosyn
Application development services are provided from Vapi, India.gtbl.in

Business activity

The main business activity of Gujarat Themis Biosyn is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Gujarat Themis Biosyn Ltd, buy the company report.

Financials of Gujarat Themis Biosyn Ltd

FY 2025-26 filings available

Gujarat Themis Biosyn Ltd reported revenue of ₹165.82 Cr (up 10% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹166 Cr
+10.0% YoY
EBITDA
₹76.41 Cr
+11.0% YoY
Profit After Tax
₹46.67 Cr
-4.3% YoY
Net Worth
₹288 Cr
+15.9% YoY
Total Assets
₹451 Cr
+61.2% YoY
Total Debt
₹162 Cr
+431.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16615117014811590.5685.12
Revenue growth+10.0%-11.2%+14.4%+29.2%+26.8%+6.4%-
EBITDA76.4168.8478.7273.6458.0540.3331.84
EBITDA margin+46.1%+45.7%+46.4%+49.6%+50.5%+44.5%+37.4%
Profit before tax62.0865.5579.3377.4759.0440.8931.26
Net profit46.6748.7859.1557.9743.6330.1723.05
Net profit margin+28.1%+32.4%+34.8%+39.1%+38.0%+33.3%+27.1%
EPS (₹)4.284.488.1439.9030.0320.7716.30
Balance sheet
Total assets45128020515010575.2950.84
Net worth28824820114910369.9442.19
Total debt16230.472.770.421.174.838.15
Cash & bank6.0912.558.169.3312.3527.642.08
Net working capital42.7432.2632.9546.8761.9851.3216.75
Cash flow
Cash from operations48.7891.0364.2139.4840.3110.530.63
Cash from investing(172)(112)(55.21)(20.41)(29.83)(2.25)(2.98)
Cash from financing11526.01(8.59)(13.27)(14.00)(5.16)2.10
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.7944.2343.3742.3535.8737.7439.5234.72
Revenue growth (YoY)+22.1%+17.2%+9.7%+22.0%-7.6%---
Other income0.130.920.420.820.271.350.240.32
Total expenses23.0024.8722.0621.4121.9521.7020.6519.33
EBITDA20.7919.3621.3120.9413.9216.0418.8715.39
EBITDA margin+47.5%+43.8%+49.1%+49.4%+38.8%+42.5%+47.7%+44.3%
Depreciation3.974.043.892.962.031.231.561.44
Interest1.791.910.960.040.040.070.140.08
Profit before tax15.1614.3316.8818.7612.1216.0917.4114.19
Tax4.103.454.414.493.064.094.433.63

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.7944.2343.3742.3535.8737.7439.5234.72
Revenue growth (YoY)+22.1%+17.2%+9.7%+22.0%-7.6%---
Other income0.130.920.420.820.271.350.240.32
Total expenses23.0024.8722.0621.4121.9521.7020.6519.33
EBITDA20.7919.3621.3120.9413.9216.0418.8715.39
EBITDA margin+47.5%+43.8%+49.1%+49.4%+38.8%+42.5%+47.7%+44.3%
Depreciation3.974.043.892.962.031.231.561.44
Interest1.791.910.960.040.040.070.140.08
Profit before tax15.1614.3316.8818.7612.1216.0917.4114.19
Tax4.103.454.414.493.064.094.433.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16615117014811590.5685.12
Revenue growth+10.0%-11.2%+14.4%+29.2%+26.8%+6.4%-
Other income2.432.444.386.594.053.271.70
Total expenses89.4181.9691.1074.7556.8050.2353.28
Employee cost14.9911.4410.217.757.087.116.43
EBITDA76.4168.8478.7273.6458.0540.3331.84
EBITDA margin+46.1%+45.7%+46.4%+49.6%+50.5%+44.5%+37.4%
Depreciation12.925.373.542.582.231.731.36
Interest3.840.360.230.180.830.980.92
Profit before tax62.0865.5579.3377.4759.0440.8931.26
Tax15.4116.7720.1819.5015.4110.717.59
Net profit46.6748.7859.1557.9743.6330.1723.05
Net profit margin+28.1%+32.4%+34.8%+39.1%+38.0%+33.3%+27.1%
EPS (₹)4.284.488.1439.9030.0320.7716.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.9010.907.267.267.267.267.26
Reserves & surplus27723719414296.0662.6834.93
Shareholders' funds (net worth)28824820114910369.9442.19
Secured loans16029.890.000.000.000.000.00
Unsecured loans1.950.582.770.421.174.838.15
Total debt16230.472.770.421.174.838.15
Total liabilities45128020515010575.2950.84
Assets
Gross block31759.3351.2144.0428.2425.5221.93
Net block28941.2938.0232.6619.4318.9517.08
Capital work in progress12118491.2220.5912.702.070.36
Investments0.000.000.000.000.000.000.01
Inventories15.425.053.3314.6211.616.056.03
Sundry debtors60.9231.2427.0317.9125.1214.7120.23
Cash & bank balances6.0912.558.169.3312.3527.642.08
Loans & advances6.363.149.0519.8729.3114.920.79
Total current assets88.7951.9847.5761.7378.3963.3229.13
Total current liabilities46.0519.7214.6214.8616.4112.0012.38
Net working capital42.7432.2632.9546.8761.9851.3216.75
Total assets45128020515010575.2950.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.696.476.060.263.970.861.12
Net cash from operating activities48.7891.0364.2139.4840.3110.530.63
Net cash from investing activities(172)(112)(55.21)(20.41)(29.83)(2.25)(2.98)
Net cash from financing activities11526.01(8.59)(13.27)(14.00)(5.16)2.10
Net change in cash(8.57)5.220.415.79(3.51)3.12(0.26)
Closing cash6.0912.558.169.3312.3527.642.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.0%-11.2%+14.4%+29.2%+26.8%+6.4%-
EBITDA growth+11.0%-12.6%+6.9%+26.9%+43.9%+26.7%-
PBT growth-5.3%-17.4%+2.4%+31.2%+44.4%+30.8%+282.2%
Net income growth-4.3%-17.5%+2.0%+32.9%+44.6%+30.9%-
Revenue CAGR (3Y)+3.8%+9.5%+23.3%+20.4%+40.9%+32.7%+33.6%
EBITDA CAGR (3Y)+1.2%+5.9%+25.0%+32.3%+99.2%+86.3%+74.0%
Profitability & leverage
Net income margin+28.1%+32.4%+34.8%+39.1%+38.0%+33.3%+27.8%
Return on capital employed+18.1%+27.2%+44.8%+60.9%+66.4%+66.4%+84.8%
Return on net worth+17.4%+21.7%+33.8%+45.9%+50.4%+53.8%+78.0%
Debt / equity0.360.070.010.010.030.120.23
Long-term debt / equity0.300.070.000.000.010.040.05
Interest cover6.050.570.310.251.492.543.02
Efficiency & per share
Fixed asset turnover0.882.733.574.114.273.824.25
Inventory turnover16.2035.9918.9211.3113.0114.9926.73
Debtors turnover3.605.187.566.905.775.186.54
EPS (₹)4.284.488.1439.9030.0320.7716.30
Dividend per share (₹)0.670.671.005.4011.000.001.65
Book value per share (₹)26.4122.7927.72102.6671.1148.1429.04

To see the full year-wise statements and ratios of Gujarat Themis Biosyn Ltd, buy the company report.

Board of directors of Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn has 7 current directors and 27 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Dinesh Shantilal Patel
Also directs: Themis Medicare Limited, Dr. Themis Private Limited, Richter Themis Medicare (India) Private Limited and 4 more
Director25 May 199234 Years 5 MonthsCurrent
Sachin Dinesh Patel
Also directs: Themis Medicare Limited, Dr. Themis Private Limited, Richter Themis Medicare (India) Private Limited and 5 more
Managing Director25 Oct 200818 Years 0 MonthsCurrent
Kirandeep Kaur Madan
Also directs: Sanskar India Foundation
Director01 May 20215 Years 6 MonthsCurrent
Rajneesh Kedarnath Anand
Also directs: Themis Medicare Limited, Richter Themis Medicare (India) Private Limited, Long Island Nutritionals Private Limited
Additional Director10 Nov 20250 Years 11 MonthsCurrent
Nihar Ajay Parikh
Also directs: Gift Trunk LLP, Kusumgar Limited, Vyox Labs Private Limited and 3 more
Director01 Aug 20251 Years 3 MonthsCurrent
Hitesh Dharmasinh Gajaria
Also directs: Datamatics Global Services Limited, Parag Parikh Financial Advisory Services Limited
Director14 May 20242 Years 5 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Auditor

Gujarat Themis Biosyn Ltd is audited by GMJ & CO for the financial year 2025.

Auditor firmFinancial yearFirm registration number
GMJ & COFY 2025103429W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 70.90%, foreign institutional investors hold 1.80%, domestic institutional investors hold 1.10% and retail and other public shareholders hold 26.20%.

Promoters: 70.90%DII (Domestic Institutional): 1.10%FII (Foreign Institutional): 1.80%Retail & Others: 26.20%
Sep 2026
QUARTER
70.90% Promoters
1.10% DII (Domestic Institutional)
1.80% FII (Foreign Institutional)
26.20% Retail & Others
Promoter holding - history
Now 70.90% · Sep 2026High 70.90% · Dec 2025Low 70.90% · Dec 2025
69%69.8%70.5%71.3%72%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 70.90%Mar 2026: 70.90%Jun 2026: 70.90%Sep 2026: 70.90%70.90%70.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters70.90%70.90%70.90%70.90%
Public29.10%29.10%29.10%29.10%

Charges & borrowings

Open charges
₹197.18 Cr
Satisfied charges
₹48.84 Cr
Breakdown by lending institutions
Others₹196.43 Cr
The Vysya Bank Ltd.₹0.75 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
26 Feb 2026101248763Others₹65 CrOpen
29 Sep 2025101170596Others₹50 CrOpen
22 Nov 2024101008206Others₹80 CrOpen
17 Jun 2024100983458Others₹1.43 CrOpen
19 Oct 200090102055The Vysya Bank Ltd.₹75 LakhOpen

To see the full charge records of Gujarat Themis Biosyn Ltd, buy the company report.

Total charge records: 17 View all charges

Deals & funding

Gujarat Themis Biosyn Ltd has 8 deals on record (8 market trades); the latest was in September 2026.

Total deals
8
Market trades
8

Deals on record (5 of 8)

WhenDealAmountParties
Sep 2026Market trade₹26.82 CrBuyer: L7 Hitech Private Limited
Seller: L7 Hitech Private Limited
Apr 2026Market trade₹21.72 CrBuyer: NK Securities Research Private Limited
Seller: NK Securities Research Private Limited
Dec 2023Market trade₹64.61 CrBuyer: Mc Jain Infoservices Private Limited
Seller: Pharmaceutical Business Group I Ltd
Apr 2017Market trade₹75.3 LakhBuyer: an individual
Seller: an individual
Mar 2015Market trade₹35.9 LakhBuyer: an individual
Seller: an individual

To see the full deal history of Gujarat Themis Biosyn Ltd, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Gujarat Themis Biosyn Ltd was last rated by Care on 04 Aug 2022.

Rating agencyRated onRating
Care04 Aug 2022

To see the full credit ratings and regulatory alerts of Gujarat Themis Biosyn Ltd, buy the company report.

MSME payment delays

Gujarat Themis Biosyn Ltd has 13 MSME Form 1 returns on record between 2019 and 2023, listing 668 overdue payments to 14 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 14)

SupplierAmount dueDue sinceReported on
an individual supplier
Kalpana Agencies Private Limited
an individual supplier
an individual supplier
Ganeshkrupa Chemicals and Fertilisers Private Limited

To see the full MSME payment records of Gujarat Themis Biosyn Ltd, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Gujarat Themis Biosyn Ltd has a workforce of 354 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.

Employee count
354
Active EPFO establishments
1
Employee growth
16.83%

GST

Gujarat Themis Biosyn has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
24AABCG0802C1ZJGujaratActive01 Jul 2017

To see the full GST registrations and return filing status of Gujarat Themis Biosyn Ltd, buy the company report.

Recent activity

Gujarat Themis Biosyn Ltd has 55 board changes on record since 1991: 31 appointments and 24 cessations. The latest: Rajneesh Kedarnath Anand was appointed as Additional Director on 10 Nov 2025.

Charges
A charge with Others of Rs. 65.00 Cr registered on 26 Feb 2026 with Charge ID 101248763 was modified on 16 May 2026.
Filing
Gujarat Themis Biosyn Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 65.00 Cr with Charge ID 101248763 was registered on 26 Feb 2026.
Appointed
Rajneesh Kedarnath Anand was appointed as Additional Director.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101170596 was registered on 29 Sep 2025.
Ceased
Siddharth Yogesh Kusumgar ceased to be Director.
AGM
Gujarat Themis Biosyn Ltd last Annual general meeting of members was held on 12 Sep 2025 as per latest MCA records.
Appointed
Nihar Ajay Parikh was appointed as Director.
Charges
A charge registered on 15 May 2000 via Charge ID 90096661 with Others was fully satisfied on 29 Nov 2024.
Charges
A charge with Others amounted to Rs. 80.00 Cr with Charge ID 101008206 was registered on 22 Nov 2024.
Ceased
Vikram Dulerai Sanghvi ceased to be Director.
Appointed
Kumarapuram Gopalakrishnan Ananthakrishnan was appointed as Director.

78 earlier events are in the company report.

News

Gujarat Themis Biosyn: Company Finalizes Purchase Of Japan-Based Microbiopharm Japan Co., Ltd. To Enhance Fermentation Skills, Product Range, And Global Presence.
18 Sep 2026 · Exchange Update

Frequently asked questions

Gujarat Themis Biosyn is an active public limited company based in Valsad, Gujarat, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 11 December 1981 (45+ years old) and is registered under CIN L24230GJ1981PLC004878. Listed on BSE: 506879 and NSE: GUJTHEM.

Gujarat Themis Biosyn reported revenue of ₹165.82 Cr for FY 2025-26 (up 10% YoY) based on standalone financials.

Gujarat Themis Biosyn has 7 current directors:

The latest financial statements of Gujarat Themis Biosyn on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 12 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Gujarat Themis Biosyn is 24AABCG0802C1ZJ, registered in Gujarat.

The CIN (Corporate Identification Number) of Gujarat Themis Biosyn is L24230GJ1981PLC004878. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Gujarat Themis Biosyn is a listed company as per MCA records. Its shares are listed on both BSE (code: 506879) and NSE (symbol: GUJTHEM).

Gujarat Themis Biosyn has 125 court cases on record: 29 filed by the company and 96 filed against it. 12 are pending. Most are in the district courts.

Gujarat Themis Biosyn was incorporated on 11 December 1981, making it 45+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Gujarat Themis Biosyn has 8 deals on record (8 market trades); the latest was in September 2026.

Rajneesh Kedarnath Anand was appointed as Additional Director on 10 Nov 2025. Siddharth Yogesh Kusumgar ceased to be Director on 20 Sep 2025. Nihar Ajay Parikh was appointed as Director on 01 Aug 2025. Gujarat Themis Biosyn has 55 board changes on record in total.